IL287901B2 - Process for preparing CLC-1 chloride channel inhibitors - Google Patents
Process for preparing CLC-1 chloride channel inhibitorsInfo
- Publication number
- IL287901B2 IL287901B2 IL287901A IL28790121A IL287901B2 IL 287901 B2 IL287901 B2 IL 287901B2 IL 287901 A IL287901 A IL 287901A IL 28790121 A IL28790121 A IL 28790121A IL 287901 B2 IL287901 B2 IL 287901B2
- Authority
- IL
- Israel
- Prior art keywords
- phenoxy
- dihydroisoxazol
- bromo
- butoxy
- propanoate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181262 | 2019-06-19 | ||
| PCT/EP2020/067065 WO2020254554A1 (en) | 2019-06-19 | 2020-06-19 | Process for the preparation of clc-1 chloride channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL287901A IL287901A (en) | 2022-01-01 |
| IL287901B1 IL287901B1 (en) | 2024-10-01 |
| IL287901B2 true IL287901B2 (en) | 2025-02-01 |
Family
ID=66999603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287901A IL287901B2 (en) | 2019-06-19 | 2020-06-19 | Process for preparing CLC-1 chloride channel inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12221425B2 (https=) |
| EP (1) | EP3986878B1 (https=) |
| JP (1) | JP7595945B2 (https=) |
| KR (1) | KR102900834B1 (https=) |
| CN (1) | CN113993852B (https=) |
| AR (1) | AR119198A1 (https=) |
| AU (1) | AU2020298092B2 (https=) |
| BR (1) | BR112021025588A2 (https=) |
| CA (1) | CA3137672A1 (https=) |
| ES (1) | ES3000437T3 (https=) |
| HU (1) | HUE069104T2 (https=) |
| IL (1) | IL287901B2 (https=) |
| MX (1) | MX2021013507A (https=) |
| PL (1) | PL3986878T3 (https=) |
| SG (1) | SG11202111122RA (https=) |
| TW (1) | TWI849152B (https=) |
| WO (1) | WO2020254554A1 (https=) |
| ZA (1) | ZA202107653B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4593829A1 (en) | 2022-09-30 | 2025-08-06 | NMD Pharma A/S | Compositions and methods for treating myasthenia gravis |
| WO2024180199A1 (en) | 2023-03-02 | 2024-09-06 | Nmd Pharma A/S | Compositions and methods for treating charcot–marie–tooth disease |
| JP2026508357A (ja) | 2023-03-02 | 2026-03-10 | エヌエムディー ファーマ エー／エス | 脊髄性筋萎縮症を処置するための組成物及び方法 |
| EP4731200A1 (en) | 2023-06-20 | 2026-04-29 | NMD Pharma A/S | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| GB0524428D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| WO2009097970A1 (de) * | 2008-02-05 | 2009-08-13 | Sanofi-Aventis | Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel |
| JP2015505560A (ja) * | 2012-02-03 | 2015-02-23 | ゾエティス・エルエルシー | 抗寄生虫薬としてのキラルイソオキサゾリンアゼチジン誘導体の製造法 |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| US10385028B2 (en) * | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
-
2020
- 2020-06-19 BR BR112021025588A patent/BR112021025588A2/pt unknown
- 2020-06-19 IL IL287901A patent/IL287901B2/en unknown
- 2020-06-19 ES ES20734157T patent/ES3000437T3/es active Active
- 2020-06-19 SG SG11202111122RA patent/SG11202111122RA/en unknown
- 2020-06-19 EP EP20734157.9A patent/EP3986878B1/en active Active
- 2020-06-19 CN CN202080043796.2A patent/CN113993852B/zh active Active
- 2020-06-19 HU HUE20734157A patent/HUE069104T2/hu unknown
- 2020-06-19 TW TW109120910A patent/TWI849152B/zh active
- 2020-06-19 US US17/619,312 patent/US12221425B2/en active Active
- 2020-06-19 JP JP2021569300A patent/JP7595945B2/ja active Active
- 2020-06-19 MX MX2021013507A patent/MX2021013507A/es unknown
- 2020-06-19 CA CA3137672A patent/CA3137672A1/en active Pending
- 2020-06-19 AR ARP200101735A patent/AR119198A1/es unknown
- 2020-06-19 AU AU2020298092A patent/AU2020298092B2/en active Active
- 2020-06-19 KR KR1020217037880A patent/KR102900834B1/ko active Active
- 2020-06-19 WO PCT/EP2020/067065 patent/WO2020254554A1/en not_active Ceased
- 2020-06-19 PL PL20734157.9T patent/PL3986878T3/pl unknown
-
2021
- 2021-10-11 ZA ZA2021/07653A patent/ZA202107653B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3986878A1 (en) | 2022-04-27 |
| HUE069104T2 (hu) | 2025-02-28 |
| BR112021025588A2 (pt) | 2022-02-01 |
| IL287901A (en) | 2022-01-01 |
| PL3986878T3 (pl) | 2025-01-20 |
| EP3986878C0 (en) | 2024-09-25 |
| CN113993852A (zh) | 2022-01-28 |
| TWI849152B (zh) | 2024-07-21 |
| US12221425B2 (en) | 2025-02-11 |
| KR102900834B1 (ko) | 2025-12-16 |
| AU2020298092A1 (en) | 2021-11-18 |
| CN113993852B (zh) | 2024-12-17 |
| SG11202111122RA (en) | 2021-11-29 |
| MX2021013507A (es) | 2021-12-10 |
| TW202115003A (zh) | 2021-04-16 |
| AU2020298092A8 (en) | 2025-04-24 |
| CA3137672A1 (en) | 2020-12-24 |
| WO2020254554A1 (en) | 2020-12-24 |
| ES3000437T3 (en) | 2025-02-28 |
| JP2022537493A (ja) | 2022-08-26 |
| JP7595945B2 (ja) | 2024-12-09 |
| IL287901B1 (en) | 2024-10-01 |
| AU2020298092B2 (en) | 2025-09-25 |
| ZA202107653B (en) | 2023-05-31 |
| EP3986878B1 (en) | 2024-09-25 |
| KR20220022895A (ko) | 2022-02-28 |
| AR119198A1 (es) | 2021-12-01 |
| US20220298124A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287901B2 (en) | Process for preparing CLC-1 chloride channel inhibitors | |
| TWI345562B (en) | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof | |
| KR100445539B1 (ko) | 치환된2,4-이미다졸리딘디온화합물및이를함유하는약제학적조성물 | |
| KR20190004742A (ko) | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 | |
| KR20200115468A (ko) | 신경근 장애 치료용 화합물 | |
| CN106458873A (zh) | 磺酰胺化合物和它们作为stat5抑制剂的用途 | |
| WO2020254558A1 (en) | 5-[(1s)-1-(4-bromophenoxy)ethyl]-2h-tetrazole derivatives and related compounds as clc-1 ion channel inhibitors for treating neuromuscular disorders | |
| JP7662196B2 (ja) | 神経筋障害の治療のための化合物 | |
| WO2017022733A1 (ja) | ピペラジン誘導体 | |
| WO2019074822A1 (en) | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE | |
| HK40068865A (en) | Process for the preparation of clc-1 chloride channel inhibitors | |
| HK40068865B (en) | Process for the preparation of clc-1 chloride channel inhibitors | |
| DE69402004T2 (de) | Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen | |
| DE69614508T2 (de) | Thiol derivate mit metallopeptidase inhibierender aktivitat | |
| KR102437095B1 (ko) | 캐스파제 저해제의 프로드럭 | |
| KR100758317B1 (ko) | 몰폴린-2-온 유도체를 포함하는 ｔ-형 칼슘 채널 차단용조성물 | |
| WO2026057052A1 (zh) | 一种il-23受体抑制剂及其制备方法和用途 | |
| JP2017141185A (ja) | プロレニン受容体リガンド及びアンタゴニスト | |
| EA052578B1 (ru) | Твердые формы n-(2-(4-цианотиазолидин-3-ил)-2-оксоэтил)-6-морфолинохинолин-4-карбоксамида | |
| WO2012163925A1 (en) | Substituted terpyridines |